Kuste Biopharma
At KUSTE we focus on two therapeutics areas
Bladder Pain Syndrome/IC
Kuste develops therapies for unmet medical inflammatory urological diseases such as Bladder Pain Syndrome/Interstitial Cystitis
Inflammatory Bowel Diseases
KUSTE prioritises areas of GI associated with high unmet need, such as inflammatory bowel disease.
Development
Two small peptides acting in the JNK inhibition, have reached up to Phase 3 results.
We are always Focused on
KEY FIGURES
Proprietary molecules
10+ years extensively studied, proven safe and efficacious JNK inhibitors for a variety of therapeutic applications.
JNK INHIBITION
Inhibitors of the JNK pathway have a proven therapeutic impact in the treatment of inflammatory diseases.
Launching studies
Launching clinical studies for the unmet clinical need of BPS/IC and preclinical on other inflammatory pathologies e.g. IBD
Discover the team
Governance
Read more about our Scientific Advisory Board and Management Team…
